End of study

Breast cancer affect around 52 000 women in France each year. Amongst them, 7% are less than 40 years old and 2% are in between 25 and 35 years old. Significant therapeutic advances have improved the prognostic of these patients. They will all most likely to received chemotherapy. Despite the fact that chemotherapy has many side effects, these women do question the impact of the treatment on their ability to procreate.

On 06/08/04 law basis, each patient is allowed to preserve gametes or germinal tissues when medical care potentially affect fertility.

Functional evaluation of ovarian reserve could help comprehend new chemotherapy protocols, provide fertility information, and help individualize fertility preservation supports.

Principal objective is to ensure the absence of ovarian stimulation's side effects and assess chemotherapy effects on child carrying potential.

Inclusion Criteria:

• 18 ≤ age < 38
• breast cancer histologically proved
• under the control of an adjuvant chemotherapy or neo adjuvant chemotherapy
• verbal agreement given

Exclusion Criteria:

• age ≥ 38
• metastatic breast cancer
• non able to follow the design of the study (geographic, social or psychological reasons)

young female, treated for non metastatic breast cancer